Dr. O'Sullivan on Radium-223 With Enzalutamide and Abiraterone in mCRPC

Video

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry, and Biomedical Sciences, Centre for Cancer Research and Biology, Northern Ireland Cancer Centre, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program (EAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

The study, which enrolled 921 patients with mCRPC, examined patients with similar criteria as seen in the ALSYMPCA trial. This criteria includes bone metastases, good liver function, and a performance stage >2. Patients in the EAP were offered open-label radium-223 with six injections combined with best standard of care.

The toxicity profile of radium-223 includes low rates of hematological toxicities, O’Sullivan says. Similar toxicities were experienced when patients additionally received agents such as enzalutamide and abiraterone. These hypothesis-generating data suggest that patients receiving enzalutamide and/or abiraterone simultaneously with radium-223 may have improved overall survival.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD